London · Delayed Price · Currency is GBP · Price in USD Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of GBP 34.59 million. The enterprise value is 11.09 million.
| Market Cap | 34.59M |
| Enterprise Value | 11.09M |
Important Dates
The next estimated earnings date is Thursday, March 12, 2026.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 12.30M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +92.00% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 0.66% |
| Owned by Institutions (%) | 13.81% |
| Float | 5.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -2.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.38 |
Financial Position
The company has a current ratio of 4.57
| Current Ratio | 4.57 |
| Quick Ratio | 4.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.44 |
| Interest Coverage | -29.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -33.50% |
| Return on Invested Capital (ROIC) | -139.52% |
| Return on Capital Employed (ROCE) | -93.21% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.20M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Q32 Bio has paid 15,623 in taxes.
| Income Tax | 15,623 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.72% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +26.72% |
| 50-Day Moving Average | 3.55 |
| 200-Day Moving Average | 2.41 |
| Relative Strength Index (RSI) | 52.12 |
| Average Volume (20 Days) | 1,991 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.10 |
Income Statement
| Revenue | n/a |
| Gross Profit | -19.63M |
| Operating Income | -32.36M |
| Pretax Income | -31.30M |
| Net Income | -31.32M |
| EBITDA | -32.05M |
| EBIT | -32.36M |
| Earnings Per Share (EPS) | -2.57 |
Balance Sheet
The company has 36.48 million in cash and 12.67 million in debt, with a net cash position of 23.82 million.
| Cash & Cash Equivalents | 36.48M |
| Total Debt | 12.67M |
| Net Cash | 23.82M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -13.72M |
| Book Value Per Share | -1.12 |
| Working Capital | 29.53M |
Cash Flow
In the last 12 months, operating cash flow was -28.86 million and capital expenditures -1,488, giving a free cash flow of -28.86 million.
| Operating Cash Flow | -28.86M |
| Capital Expenditures | -1,488 |
| Free Cash Flow | -28.86M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -92.00% |
| Shareholder Yield | -92.00% |
| Earnings Yield | -90.53% |
| FCF Yield | -83.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |